Vein Tissue Expression of Matrix Metalloproteinase as Biomarker for Hemodialysis Arteriovenous Fistula Maturation

Abstract

Failure of arteriovenous fistula (AVF) maturation is attributed to impaired vein remodeling. The purpose of this study is to identify whether vein matrix metalloproteinase (MMP) expression and activity is associated with AVF maturation. Patients with renal insufficiency undergoing surgery had their vein segments harvested and snap-frozen at time of AVF construction. Expression of MMP-2, MMP-9, membrane type-1 MMP (MT1-MMP), tissue inhibitor of metallopreoteinases type 2 (TIMP-2), and TIMP-4 were measured using zymography and Western blotting techniques. Of 14 patients enrolled, 9 had successful maturation and 5 had failure of AVF maturation. Significantly higher levels of MT1-MMP (an MMP-2 activator; P = .01), TIMP-2 (an MMP-2 inhibitor; P = .03), MMP-2 latent (P = .02), and MMP-2 total (P = .03) were associated with AVF maturation. There was a trend toward higher levels of TIMP-4 in the successful group (P = .18). These data demonstrate a positive relationship between MMP-2 expression in veins and AVF maturation. MMP-2 could serve as a potential preoperative marker to predict maturation.

Keywords

vessel remodeling matrix metalloproteinase hemodialysis arteriovenous

Get full access to this article

View all access options for this article.

References

Kopple JD National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2001;37(1 suppl 2):S137-S181.

Dember LM , Beck GJ , Allon M. , et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA. 2008;299(18):2164-2171.

Dixon BS

Why don’t fistulas mature?

Kidney Int. 2006;70(8): 1413-1422.

Tonelli M. Randomized trials in hemodialysis patients: time to step up to the plate. JAMA. 2008;299(18):2205-2207.

Berceli SA , Jiang Z. , Klingman NV , Schultz GS , Ozaki CK Early differential MMP-2 and -9 dynamics during flow-induced arterial and vein graft adaptations. J Surg Res. 2006;134(2):327-334.

Chan CY , Chen YS , Ma MC , Chen CF Remodeling of experimental arteriovenous fistula with increased matrix metalloproteinase expression in rats. J Vasc Surg. 2007;45(4):804-811.

Chase AJ , Newby AC Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodelling. J Vasc Res. 2003;40(4): 329-343.

Kargozaran H. , Yuan SY , Breslin JW , et al. A role for endothelial-derived matrix metalloproteinase-2 in breast cancer cell transmigration across the endothelial-basement membrane barrier. Clin Exp Metastasis. 2007 ;24(7):495-502.

Goodall S. , Crowther M. , Hemingway DM , Bell PR , Thompson MM Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation. 2001;104(3):304-309.

10.

Alpert JS , Thygesen K. , Antman E. , Bassand JP Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36(3):959-969.

11.

Tsimikas S. , Willerson JT , Ridker PM C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol. 2006;47(8 suppl): C19-C31.

12.

Golledge J. , Tsao PS , Dalman RL , Norman PE Circulating markers of abdominal aortic aneurysm presence and progression. Circulation. 2008 ;118(23):2382-2392.

13.

Guo M. , Daines D. , Tang J. , et al. Fibrinogen-gamma C-terminal fragments induce endothelial barrier dysfunction and microvascular leak via integrin-mediated and RhoA-dependent mechanism. Arterioscler Thromb Vasc Biol. 2009;29(3):394-400.

14.

Chou CY , Kuo HL , Yung YF , Liu YL , Huang CC C-reactive protein predicts vascular access thrombosis in hemodialysis patients . Blood Purif. 2006;24(4):342-346.

15.

Kirkpantur A. , Arici M. , Altun B. , et al. Association of serum lipid profile and arteriovenous fistula thrombosis in maintenance hemodialysis patients . Blood Purif. 2008;26(4):322-332.

16.

Biuckians A. , Scott EC , Meier GH , Panneton JM , Glickman MH The natural history of autologous fistulas as first-time dialysis access in the KDOQI era. J Vasc Surg . 2008;47(2):415-421; discussion 420-421.

17.

Misra S. , Fu AA , Anderson JL , et al. The rat femoral arteriovenous fistula model: increased expression of matrix metalloproteinase-2 and -9 at the venous stenosis. J Vasc Interv Radiol. 2008;19(4): 587-594.

18.

Cheema BS Review article: tackling the survival issue in end-stage renal disease: time to get physical on haemodialysis. Nephrology ( Carlton). 2008;13(7):560-569.

19.

Guerin AP , Pannier B. , Metivier F. , Marchais SJ , London GM Assessment and significance of arterial stiffness in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 2008; 17(6):635-641.

20.

Ethier J. , Mendelssohn DC , Elder SJ , et al. Vascular access use and outcomes: an international perspective from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2008;23(10):3219-3226.

21.

Misra S. , Fu AA , Rajan DK , et al. Expression of hypoxia inducible factor-1 alpha, macrophage migration inhibition factor, matrix metalloproteinase-2 and -9, and their inhibitors in hemodialysis grafts and arteriovenous fistulas. J Vasc Interv Radiol. 2008; 19(2 pt 1):252-259.

22.

Galis ZS , Khatri JJ Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90(3):251-262.